3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Neoplasms
1
Metastatic Urothelial Cancer
1
Kidney Neoplasms
1
Kidney Diseases
1
Carcinoma, Renal Cell
1
Interventions
Carboplatin
27
pembrolizumab
26
Cisplatin
24
Paclitaxel
21
Nivolumab
19
Gemcitabine
16
Pemetrexed
14
Rituximab
14
Ipilimumab
12
Cyclophosphamide
11
Dexamethasone
11
Fluorouracil
10
Capecitabine
9
Docetaxel
9
durvalumab
9
trastuzumab deruxtecan
9
Lenalidomide
8
Oxaliplatin
8
atezolizumab
8
Doxorubicin
7
daratumumab
7
osimertinib
7
Bortezomib
6
Cytarabine
6
Leucovorin
6
Trastuzumab
6
olaparib
6
venetoclax
6
130-nm albumin-bound paclitaxel
5
Ado-Trastuzumab Emtansine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
avelumab
×
1 year
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA